Anne C. Bay-Jensen

Alligator Bioscience AB announced positive top-line results from the OPTIMIZE-1 Phase II trial in pancreatic cancer, revealing that mitazalimab combined with mFOLFIRINOX achieved a 40.4% overall response rate (ORR), a median duration of response (DoR) of 12.5 months, and a median overall survival (mOS) of 14.3 months. This compares favorably to the 11.1 months mOS seen with first-line chemotherapies FOLFIRINOX and NALIFIROX. With more than half of the patients still in the study at the primary analysis, the 18-month survival follow-up data was presented at American Society of Clinical Oncology (ASCO) 2024. Get Ahead with Expert Insights and Full Analysis through DelveInsight Business Research LLP's Exclusive ASCO 2024 Coverage: https://lnkd.in/gZDPhuxR #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #mCRPC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

17

Tenboron Oy is developing boron carrier substances for boron neutron capture therapy (BNCT), a cancer treatment. The production of the antibody-boron conjugate molecule is a two-step process, in which the boron part of the boron carrier is produced under Medfiles’ licence and quality system. Jari Helin, Head of CMC and leader of the molecule development project, values the quality system and facilities provided by Medfiles for drug development and manufacture. “I find that the cooperation with Medfiles is absolutely essential for our operations. It was easy to jump in, with the quality system ready and in place.” Read the client story ⬇ #cancerresearch #drugdevelopment #pharmaceuticals #BNCT #qualitysystem #GMP

23

Exciting News: Alligator Bioscience AB published on a novel bispecific antibody format. The RUBY bispecific antibody (bsAb) format features a 2 + 2 geometry, linking two Fab fragments to an IgG, with mutations for optimal chain pairing. ✅ This design facilitates the rapid creation of bsAbs meeting key development criteria. ✅ They demonstrate tailored Fc gamma receptor binding, while retaining FcRn interaction for pharmacokinetics like monoclonal antibodies (mAbs). ✅ Octet®️ BLI was used for kinetic measurements to confirm their functionality and demonstrate their antitumor potential. Read the article here: https://ow.ly/rXvy50RHXaA #OctetBLI #BLI #Biotechnology #Immunotherapy #FcReceptors #BispecificAntibodies #Pharmacokinetics #Innovation #ScienceNews #ClinicalResearch #FcGammaReceptors #ClinicalPotential #cancer

38

3 Kommentarer

Are you interested in advancing your cell-based assays and implementing human iPSC-derived disease models for your research or drug development projects? In collaboration with AbbVie, Bioneer A/S has created an on-demand webinar showcasing our capabilities with CRISPR editing. The webinar includes a detailed example of how AbbVie has established a Tau-based iPSC-derived disease model for Alzheimer's disease. This video will guide you through the process of generating CRISPR-edited iPSCs, offering tips and tricks for developing iPSCs for neurodegenerative disease research. Additionally, it features a case study on using these models in a drug screening process. If you have any questions about setting up iPSC-derived disease models for neurodegenerative diseases or are interested in creating CRISPR-edited iPSCs for your own research, feel free to reach out to Dale Shelton to schedule a meeting with our scientists. https://lnkd.in/gdW6FfPN #Tau #ipsc #neurodegenerativedisease #Bioneer #Crispr #DrugDiscovery #alzheimers

20

We're excited to announce our strategic partnership with Vipergen ApS to provide DNA encoded library (DEL) screening and integrated drug discovery services. The partnership aims to accelerate innovation in drug discovery by increasing success rates and reducing timelines through screening a billion+ small-molecule compounds either in a living cell or on a purified drug target protein. Access the full story here! https://lnkd.in/g7s7MhJ8 Commenting on the partnership our CEO, Akhil Ravi said that “The partnership with Vipergen emphasizes our commitment to accelerating innovation and customer centric approach. Vipergen’s proven track record, with more than 90 partnerships with big pharma and biotech companies, and their streamlined hit finding platform, makes Vipergen the ideal strategic partner for us." Nils Jakob Vest Hansen, Ph.D., CEO of Vipergen, added that “we are excited to partner with Aurigene, a global CRDMO focused on customer service. Aurigene’s drug discovery capabilities and global reach makes a perfect match for Vipergen. I am looking forward to a successful partnership, and to offering our proprietary technologies to global customers.   #collaboration #partnership #media #drugdiscovery #screening #DNA #encoded #library #innovation #CRDMO #aurigene  

120

1 Kommentar

Adcendo ApS, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, announced the successful completion of a second Series A extension financing, raising a total of 98M EUR. https://lnkd.in/dARvXshs #TechNews #StayInformed #StayAhead #dailydose #followus #staytuned #stayconnected #technews #technology #trending #trendingnow #trendingnews #explore #explorepage #techdogs

4

Asgard Therapeutics has today had a landmark paper published in the prestigious journal Science, demonstrating in vivo proof-of-concept for its first-in-class approach to cancer immunotherapy.    Novel data published in the study, co-led by the Filipe Pereira Lab at Lund University, demonstrate that our lead product AT-108 reprograms tumor cells, directly within the immunosuppressed tumor microenvironment, into antigen-presenting dendritic cells. This causes strong, antigen-specific, anti-tumor responses to be mounted, resulting in durable tumor shrinkage even upon metastatic challenge.    The study paves the way for human clinical trials of AT-108 in vivo immune cell reprogramming for cancer immunotherapy.   The graphic depicts a tumor cell being ‘unlocked’ by AT-108 and consequently transformed into an antigen-presenting dendritic cell. The dendritic cell is depicted as shining as it illuminates the way for the immune system to target ‘cold and dark’ tumors - thus generating robust, long-lasting and systemic anti-tumor responses. Graphic by Joana C. Carvalho. Click the link in the comments below to read the press release and the paper.

359

13 Kommentarer

Lundbeck, an innovator within CNS disorders and Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, today announced the companies have entered into a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. The agreement includes an upfront payment, performance-based milestones, and royalties. “Iambic’s state-of-the-art platform - including the NeuralPLexer protein-ligand structure prediction technology - will accelerate the generation of novel candidates with a higher probability of success at reaching our patients,” said Tarek Samad, PhD, Senior Vice President, and Head of Global Research at Lundbeck. “The pace at which Iambic can both design molecules in silico and then test them in the laboratory has the potential to unlock compelling neurology targets that have eluded traditional drug discovery methods.” “We welcome the opportunity to work with industry leaders at Lundbeck and to demonstrate the potential of the Iambic platform to discover neurological medicines,” said Thomas Miller, Ph.D., Chief Executive Officer, and co-founder of Iambic. Iambic is also developing an internal pipeline of candidates, discovered using its platform that integrates AI models for protein structure prediction and wholistic drug design with high-throughput chemistry and biology experimentation. Iambic’s pipeline currently includes IAM1363, a highly selective, brain penetrant small molecule inhibitor of both wild-type and oncogenic HER2 mutants currently in a Phase 1/1b study, as well as a potential first-in-class selective dual CDK2/4 inhibitor for multiple cancer indications, an allosteric inhibitor for KIF18A, and additional new programs. This partnership reflects Lundbeck’s strong commitment to innovation across R&D. Merging the power of generative AI with expertise in developing drug candidates for brain diseases aims to significantly enhance the probability of success and reduce discovery timelines for novel therapeutics. The partnership also supports Lundbeck’s strategy of being a focused innovator in brain health. #AI #MachineLearning #Innovation #DrugDiscovery  #CNS #BrainHealth #Migraine #Partnership #Iambic #Lundbeck 

37

New long-term data for Novo Nordisk’s #Wegovy (semaglutide), published this week in Nature https://lnkd.in/drkXyH5x, has added further weight to the anti-obesity drug’s “miracle” benefits. These new findings from the large-scale SELECT trial show that patients receiving the drug sustained weight loss for up to four years. Further analyses of semaglutide data, presented at the European Society of Cardiology #HeartFailure2024 congress in Lisbon this week, also showed that heart failure-associated biomarkers decreased in patients receiving Wegovy, regardless of the extent of weight loss, suggesting direct cardiac benefits of the drug -- independent of any weight-reduction benefits. These findings add to the wave of data published for the GLP-1 RA, which has been shown to result in ~17% weight loss in people with obesity, while also reducing the risk of obesity-related comorbidities including major adverse cardiac events, heart failure, and osteoarthritis. Further benefits have also been shown for semaglutide in Type 2 Diabetes (under the brand name #Ozempic) and related comorbidities, including a 24% risk reduction in kidney disease-related events in people with T2D and chronic kidney disease. So what does this mean? This new data will grow confidence in the longer-term broad cardio-renal-metabolic benefits of semaglutide with Novo Nordisk seeking label expansions for semaglutide in obesity and T2D-related comorbidities. The impact could be even wider-reaching; with cardiac benefit data potentially supporting increased access to semaglutide in regions, including the U.S., that have historically not reimbursed anti-obesity medications. In light of this new data and its potential implications, we can expect to see Novo Nordisk continuing to drive home the message that obesity is a serious chronic disease with a significant unmet need, associated with many complications. The marketing machine behind Wegovy and Ozempic has successfully driven consumers into a frenzy to take advantage of the broad weight-loss and cardiovascular benefits of these drugs, with conventional direct-to-consumer advertising (in the U.S.) also bolstered by the Hollywood hype and social media noise behind the GLP-1 RA class. However, to date, Novo Nordisk seems to remain a victim of its own successful marketing campaigns, as it struggles to meet consumer demand, with it recently investing heavily in manufacturing plants to scale up production. And while the media hype has worked in semaglutide’s favour to date, there is increasing noise around potential side effects, with “Ozempic face” widely reported, leaving a question mark over how long Novo Nordisk may be able to control the positive narrative in the mainstream media before the tide starts to turn. Analysis authored by Solici Senior Consultant Jonathan Barrow and Consultant Alexandra Holden

32

Lundbeck is set to acquire Longboard Pharmaceuticals for $2.6Bn, gaining access to bexicaserin - a selective 5-HT2C receptor agonist in development for Dravet syndrome, Lennox-Gastaut syndrome and other developmental and epileptic encephalopathies (DEEs). Bexicaserin has shown promising anti-seizure reduction in preclinical and clinical studies and is now being evaluated in a global Phase III clinical program. This strategic deal highlights increasing M&A activity in the CNS therapy area and renewed interest in serotonergic drug development. #Bexicaserin #Neuroscience #Epilepsy https://lnkd.in/e7BYFK8h

4

We are proud to introduce the FIB-NIT™ (Fibrosis Non-Invasive Tests) biomarker panel, based on over 100 publications in relevant and peer-reviewed scientific journals. FIB-NIT™ is an innovative panel that utilizes biomarkers of fibrotic processes. These biomarkers have been proven to associate with superior pharmacodynamic and prognostic performance to investigate dynamics within fibrotic diseases, including understanding drug efficacy in such indications. When combined in the FIB-NIT™ panel, these three biomarkers offer a valuable tool for accelerating clinical trials and reducing financial burden. FIB-NIT™ achieves this by helping with patient selection and inclusion, identification of treatment responders, assessment and prediction of drug response, diagnostics without the need for invasive procedures like biopsy; or the use of expensive noninvasive screening tests that are commonly used in the clinical practice. ➡️Read our comprehensive breakdown of the FIB-NIT™ biomarkers on our website: https://lnkd.in/eCzYb4Kt #fibrosis #drugdevelopment #biomarkers #FIBNIT #drugdiscovery #clinicaltrials Diana Julie Leeming Federica Genovese Jannie M. B. Sand Rune Vestermark Sarah Rønnow Morten Asser Karsdal Andressa Zawadzki Daniel Gabor

71

🗣️''The number of complex antibody-based therapeutics is increasing, offering new hope for the treatment of complex diseases such as cancer and auto-immune diseases.'' ―Johanna Howson, Lead Applications Scientist, Purolite. Created with acid sensitivities of newer molecules in mind, DurA Cycle was designed to allow for a milder pH elution with less product loss; improving yields and increasing productivity in your #downstream purification processes. Find out more about DurA Cycle: https://bit.ly/3RZ8oRl

83

Asthma development is associated with low mucosal IL-10 during viral infections in early life. First author: Mathias Elsner Melgaard; corresponding author: Klaus Bønnelykke Read the article here: doi.org/10.1111/all.16276 This study investigated virus-specific immune mediator levels in the upper airways during respiratory illnesses in early life and the association with later asthma development. The airway immune profile during viral respiratory illnesses was characterized by high levels of type 1 and regulatory immune mediators and low levels of type 2 and type 17 immune mediators. Children later developing asthma had a reduced regulatory (IL-10) immune mediator level during viral respiratory illnesses in early life. #Allergy_journal Read more articles published in #Allergy on #asthma here: https://lnkd.in/dCVQJRc

3

It's time we move beyond "diet drugs/appetite suppressants". The GLP-1 class are quite good, and we need to complement them with new drugs that restore long-term healthy/lean energy balance. Appetite-suppressing drugs have no impact on the adipostat (level of body fat that the body DEFENDS). As a result, the body weight lost from appetite-suppressing drugs (GLP-1s) is accompanied by a drop in resting metabolic rate (well-known physiological adaptation to lower energy intake, in animals & humans). This makes is very hard/impossible to keep the weight down long term (yo-yo effect). For long-term efficacy (cure) of obesity, we need to induce the body to want to defend a lower level of body fat: decrease the adipostat. We can't fight the body's physiological regulation - and we shouldn't have to - so we need to work WITH the body. Let's work on the other side of the energy balance equation, the side that is actually dysregulated in people with obesity: adaptive metabolic rate (thermogenesis, dissipation of energy as heat=safety valve that prevents obesity). This is regulated by the amount of brown adipocytes (brown fat). Increasing/restoring healthy amount of brown fat will complement GLP-1s and improve metabolic health long term.

21

DYK? - when decisions about which treatments to prescribe are guided or informed by insights from a patient’s DNA, the odds of recovery improve. ➡️ Health systems and professional societies across Canada, the USA and the EU support the clinical use of DNA-guided prescribing with assistance from experts trained in pharmacogenetics. ⚕️ The Pillcheck integrated service combines a genetic test and expert pharmacist review to help clinicians with varied levels of expertise in pharmacology reduce the lengthy process of trial and error and minimize the risk of adverse reactions. https://lnkd.in/gKMUqr_a #patientsafety #healthtech #precisionmedicine

Alligator Bioscience AB has announced positive 18-month follow-up data from the OPTIMIZE-1 Phase 2 study of the company’s lead asset mitazalimab in 1st line metastatic pancreatic cancer. The open-label, multi-center study assessed the safety and efficacy of anti-CD40 mitazalimab in combination with standard of care chemotherapy mFOLFIRINOX, in previously untreated, chemotherapy naïve pancreatic cancer patients. The data demonstrated 18-month survival rate of 36.2% in patients treated with mitazalimab in combination with mFOLFIRINOX, compared to 18.6% reported with FOLFIRINOX alone. Alligator is continuing its preparations for the global Phase 3 registration study to evaluate mitazalimab in pancreatic cancer and the company remains on track to initiate the study in 2025.  https://lnkd.in/dVgcV5Fr

41

Pharmatest was excited to join the NK-ENGAGE consortium for a productive face-to-face meeting in Oslo! This ambitious Eurostars and Business Finland -funded R&D project is focused on creating an innovative synthetic small polypeptide for treating multiple myeloma (MM), as well as developing advanced preclinical models in the presence of human immune cells. We are proud to collaborate with a strong alliance of distinguished institutions and biotech firms, including Oncopeptides AB (publ) (Sweden), KTH Royal Institute of Technology in Stockholm, and Oslo University Hospital. The discussions we had were truly inspiring and highlighted the potential for groundbreaking advancements in MM therapy. Learn more about this exciting initiative here: https://lnkd.in/dwTtfQEi https://lnkd.in/dStH3MZR Eurostars is part of the European Partnership on Innovative SMEs. The partnership is co-funded by the European Union through Horizon Europe. #eurostars #multiplemyeloma #researchanddevelopment #preclinicalresearch

30

#CMC professionals know: cell and gene therapies are transforming medicine. 😨 But are statistics keeping pace with complex interactivities in processes? According to Lundbeck's Patricia McNeill, treatments can have 10-20+ critical quality attributes influenced by numerous interconnected process parameters. Traditional statistical approaches are not enough. 🙇‍♂️ In Philip Ramsey's words, it all comes back to dealing with 𝐜𝐨𝐦𝐩𝐥𝐞𝐱𝐢𝐭𝐲. To deal with complexity, users need 𝐩𝐫𝐞𝐝𝐢𝐜𝐭𝐢𝐨𝐧. "You have to somehow be experimenting in a way to capture this interactive behavior ... 𝐢𝐭'𝐬 𝐚𝐥𝐥 𝐚𝐛𝐨𝐮𝐭 𝐩𝐫𝐞𝐝𝐢𝐜𝐭𝐢𝐨𝐧 ... a measure of how well models you develop interpolate over the design region." To make this work possible, Predictum offers the #SVEM methodology, a machine learning approach that provides accurate predictive modeling. We invite you to learn about SVEM in the case study below. 📺 Watch the full, free webinar at predictum.com: https://bit.ly/4atDEOM -- #predictum #JMP #processdevelopment #processimprovement #drugdevelopment #pharmaceuticals

11

1 Kommentar

Here at AMLo Biosciences we are focused on developing prognostic tests for early stage #melanoma to help clinicians better identify patients' true risk of disease progression. So, we were interested to read a Norwegian study looking at the incidence and factors that accompany second primary invasive melanomas. Using retrospective data, the study revealed that older age and male sex were associated with an increased risk of a second primary tumour. The investigators advise that increased surveillance should be considered for men (especially over 50 years) for a minimum of 3 years post-initial diagnosis.  https://bit.ly/43XdbaG www.amlo-biosciences.com #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers  

7